Turn Therapeutics to Present Pipeline Updates at Healthcare Conferences, Highlights Mid-2026 Phase 2 Readout
Summary
Turn Therapeutics announced it will present pipeline updates at upcoming healthcare conferences and released an updated investor presentation detailing progress on its lead dermatology candidates, GX-03, with key clinical readouts anticipated.
Key Events
-
Upcoming Conference Presentations
CEO Brad Burnam will present at the 36th Annual Oppenheimer Healthcare Life Sciences Conference on February 25, 2026, and the 46th Annual TD Cowen Healthcare Conference on March 2, 2026, providing updates on the dermatology pipeline.
-
Updated Investor Presentation Released
The company posted an updated investor presentation to its website, offering a detailed overview of its science, pipeline, and financial highlights.
-
GX-03 Eczema Trial Progress
The presentation highlights the ongoing Phase 2 clinical trial for GX-03 in moderate-to-severe atopic dermatitis (eczema), with topline data readout expected mid-2026.
-
GX-03 Onychomycosis Phase 3 Readiness
GX-03 is positioned for Phase 3 initiation in onychomycosis (toenail fungus) by Q1 2027, following positive Phase 2 equivalent study results.
Analysis
Turn Therapeutics announced upcoming presentations at two major healthcare conferences, accompanied by an updated investor presentation. For a clinical-stage biotechnology company, these events are crucial for maintaining investor visibility and communicating pipeline progress. The investor presentation provides a comprehensive overview of their lead investigational therapy, GX-03, for moderate-to-severe atopic dermatitis (eczema), including the ongoing Phase 2 clinical trial with topline results expected mid-2026. It also highlights GX-03's readiness for Phase 3 in onychomycosis by Q1 2027, underscoring active development across multiple indications. This proactive engagement with the investment community and detailed pipeline update are important for investor confidence and potential future capital raises.
At the time of this filing, TTRX was trading at $3.81 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $113.4M. The 52-week trading range was $2.57 to $26.50. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.